Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2038 versus standard buprenorphine care for opioid dependence
ACTRN12618001759280Phase 3Completed
- Sponsor
- Camurus
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in opioid use disorder (OUD) comparing CAM2038 depot buprenorphine with Buprenorphine standard of care (2 arms). Primary endpoint: Treatment Satisfaction Questionnaire for Medication global satisfaction score. Started Oct 2018; status: completed.
02
Drugs
CAM2038buprenorphinebuprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12618001759280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001759280.